Kihoon Nam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kihoon Nam has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Olga Juliana Baker
Bond Life Sciences Center, University of Missouri, Columbia, USA
6 shared publications Gary A. Weisman
Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, MO
2 shared publicationsHarim Tavares dos Santos
Department of Oral Biology, School of Dental Medicine, University at Buffalo, The State University of New York, Buffalo NY
2 shared publications- Harim Tavares dos Santos
Department of Otolaryngology‐Head and Neck Surgery University of Missouri Columbia Missouri USA
2 shared publications - Bryan Trump
School of Dentistry and Department of Dermatology, University of Utah, Salt Lake City, UT
1 shared publication David A. Bull
Division of Cardiothoracic Surgery, Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT, USA
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10)
Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease
Sjögren's disease (SD) is an autoimmune condition characterized by chronic inflammation and impaired secretory function of the salivary glands (SG). The proresolving lipid mediator AT‐RvD1 restores SG function in SD‐like mice; however, its tissue pharmacokinetics, exposure‐response relationships, and human dose predictions remain poorly understood. Therefore, this exploratory study characterizes AT‐RvD1 tissue pharmacokinetics, develops an SG‐focused physiologically based pharmacokinetic (PBPK) model, explores the relationship between SG exposure and secretory response, and predicts human exposures relevant to clinical development. Following intravenous administration of AT‐RvD1 to SD‐like mice, concentrations were quantified in serum, submandibular gland (SMG), heart, lung, liver, and kidney. These data were used to evaluate a PBPK model incorporating the SG as the target site of action. PBPK‐predicted cumulative SMG exposure was subsequently compared with the saliva flow rate obtained after chronic AT‐RvD1 treatment. The mouse model was then used to predict systemic and SG exposure in a virtual human population across an exploratory dose range. The PBPK model described systemic and tissue pharmacokinetics, with average fold error and absolute average fold error values within predefined acceptance criteria. Human PBPK simulations predicted dose‐dependent increases in SG exposure and identified 1.5 mg/kg as a candidate dose at which predicted concentrations exceeded the preclinical pharmacological reference concentration in more than 90% of simulated subjects. Collectively, these analyses provide an experimentally informed PBPK framework for exploring AT‐RvD1 tissue exposure, exposure–response relationships, and candidate doses for future clinical evaluation in SD.
- 8 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10)
Open AccessTranslational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease
Sjögren's disease (SD) is an autoimmune condition characterized by chronic inflammation and impaired secretory function of the salivary glands (SG). The proresolving lipid mediator AT‐RvD1 restores SG function in SD‐like mice; however, its tissue pharmacokinetics, exposure‐response relationships, and human dose predictions remain poorly understood. Therefore, this exploratory study characterizes AT‐RvD1 tissue pharmacokinetics, develops an SG‐focused physiologically based pharmacokinetic (PBPK) model, explores the relationship between SG exposure and secretory response, and predicts human exposures relevant to clinical development. Following intravenous administration of AT‐RvD1 to SD‐like mice, concentrations were quantified in serum, submandibular gland (SMG), heart, lung, liver, and kidney. These data were used to evaluate a PBPK model incorporating the SG as the target site of action. PBPK‐predicted cumulative SMG exposure was subsequently compared with the saliva flow rate obtained after chronic AT‐RvD1 treatment. The mouse model was then used to predict systemic and SG exposure in a virtual human population across an exploratory dose range. The PBPK model described systemic and tissue pharmacokinetics, with average fold error and absolute average fold error values within predefined acceptance criteria. Human PBPK simulations predicted dose‐dependent increases in SG exposure and identified 1.5 mg/kg as a candidate dose at which predicted concentrations exceeded the preclinical pharmacological reference concentration in more than 90% of simulated subjects. Collectively, these analyses provide an experimentally informed PBPK framework for exploring AT‐RvD1 tissue exposure, exposure–response relationships, and candidate doses for future clinical evaluation in SD.
- 14 January 2026
- Published by Springer Nature
- p. 161-176
Emerging Trends in Salivary Gland Regeneration
- Open Access
- 16 April 2025
- Published by Elsevier in JADA Foundational Science
- Vol. 4
Current basic and preclinical research for treatment of radiation therapy–induced hyposalivation
- 16 April 2025
- Published by Elsevier in JADA Foundational Science
- Vol. 4
Open AccessCurrent basic and preclinical research for treatment of radiation therapy–induced hyposalivation
- Open Access
- 17 November 2022
- Published by Elsevier in JADA Foundational Science
- Vol. 2
A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome–like features in a mouse model
- 17 November 2022
- Published by Elsevier in JADA Foundational Science
- Vol. 2
Open AccessA combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome–like features in a mouse model
- 21 August 2022
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 70 (9) , 659-667
Tuft Cells Are Present in Submandibular Glands Across Species
Tuft cells are bottle-shaped, microvilli-projecting chemosensory cells located in the lining of a variety of epithelial tissues and, following their identification approximately 60 years ago, have been linked to immune system function in a variety of epithelia. Until recently, Tuft cells had not been convincingly demonstrated to be present in salivary glands with their detection by transmission electron microscopy only shown in a handful of earlier studies using rat salivary glands, and no follow-up work has been conducted to verify their presence in salivary glands of other species. Here, we demonstrate that Tuft cells are present in the submandibular glands of various species (i.e., mouse, pig and human) using transmission electron microscopy and confocal immunofluorescent analysis for the POU class 2 homeobox 3 (POU2F3), which is considered to be a master regulator of Tuft cell identity.
- 21 August 2022
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 70 (9) , 659-667
Tuft Cells Are Present in Submandibular Glands Across Species
Tuft cells are bottle-shaped, microvilli-projecting chemosensory cells located in the lining of a variety of epithelial tissues and, following their identification approximately 60 years ago, have been linked to immune system function in a variety of epithelia. Until recently, Tuft cells had not been convincingly demonstrated to be present in salivary glands with their detection by transmission electron microscopy only shown in a handful of earlier studies using rat salivary glands, and no follow-up work has been conducted to verify their presence in salivary glands of other species. Here, we demonstrate that Tuft cells are present in the submandibular glands of various species (i.e., mouse, pig and human) using transmission electron microscopy and confocal immunofluorescent analysis for the POU class 2 homeobox 3 (POU2F3), which is considered to be a master regulator of Tuft cell identity.
- Open Access
Cell Sheets Restore Secretory Function in Wounded Mouse Submandibular Glands
Thermoresponsive cell culture plates release cells as confluent living sheets in response to small changes in temperature, with recovered cell sheets retaining functional extracellular matrix proteins and tight junctions, both of which indicate formation of intact and functional tissue. Our recent studies demonstrated that cell sheets are highly effective in promoting mouse submandibular gland (SMG) cell differentiation and recovering tissue integrity. However, these studies were performed only at early time points and extension of the observation period is needed to investigate duration of the cell sheets. Thus, the goal of this study was to demonstrate that treatment of wounded mouse SMG with cell sheets is capable of increasing salivary epithelial integrity over extended time periods. The results indicate that cell sheets promote tissue organization as early as eight days after transplantation and that these effects endure through Day 20. Furthermore, cell sheet transplantation in wounded SMG induces a significant time-dependent enhancement of cell polarization, differentiation and ion transporter expression. Finally, this treatment restored saliva quantity to pre-wounding levels at both eight and twenty days post-surgery and significantly improved saliva quality at twenty days post-surgery. These data indicate that cell sheets engineered with thermoresponsive cell culture plates are useful for salivary gland regeneration and provide evidence for the long-term stability of cell sheets, thereby offering a potential new therapeutic strategy for treating hyposalivation.
Open AccessCell Sheets Restore Secretory Function in Wounded Mouse Submandibular Glands
Thermoresponsive cell culture plates release cells as confluent living sheets in response to small changes in temperature, with recovered cell sheets retaining functional extracellular matrix proteins and tight junctions, both of which indicate formation of intact and functional tissue. Our recent studies demonstrated that cell sheets are highly effective in promoting mouse submandibular gland (SMG) cell differentiation and recovering tissue integrity. However, these studies were performed only at early time points and extension of the observation period is needed to investigate duration of the cell sheets. Thus, the goal of this study was to demonstrate that treatment of wounded mouse SMG with cell sheets is capable of increasing salivary epithelial integrity over extended time periods. The results indicate that cell sheets promote tissue organization as early as eight days after transplantation and that these effects endure through Day 20. Furthermore, cell sheet transplantation in wounded SMG induces a significant time-dependent enhancement of cell polarization, differentiation and ion transporter expression. Finally, this treatment restored saliva quantity to pre-wounding levels at both eight and twenty days post-surgery and significantly improved saliva quality at twenty days post-surgery. These data indicate that cell sheets engineered with thermoresponsive cell culture plates are useful for salivary gland regeneration and provide evidence for the long-term stability of cell sheets, thereby offering a potential new therapeutic strategy for treating hyposalivation.
- Open Access
- 23 September 2013
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 10 (10) , 3676-3683
Synergistically Combined Gene Delivery for Enhanced VEGF Secretion and Antiapoptosis
With current pharmacological treatments, preventing the remodeling of the left ventricle and the progression to heart failure is a difficult task. Gene therapy is considered to provide a direct treatment to the long-term complications of ischemic heart diseases. Although current gene therapies that use single molecular targets seem potentially possible, they have not achieved success in the treatment of ischemic diseases. With an efficient polymeric gene carrier, PAM-ABP, we designed a synergistically combined gene-delivery strategy to enhance vascular endothelial growth factor (VEGF) secretion and to prolong its antiapoptotic effects. A hypoxia-inducible plasmid expressing both hypoxia-inducible heme oxygenase-1 (HO-1) and the Src homology domain-2 containing tyrosine phosphatase-1 microRNA (miSHP-1) as well as a hypoxia-responsive VEGF plasmid were combined in this study. The positive feedback circuit between HO-1 and VEGF and the negative regulatory role of SHP-1 in angiogenesis enhance VEGF secretion synergistically. The synergy in VEGF secretion as a consequence of the gene combination and prolonged HO-1 activity was confirmed in hypoxic cardiomyocytes and cardiomyocyte apoptosis under hypoxia and was decreased synergistically. These results suggest that the synergistic combination of VEGF, HO-1, and miSHP-1 may be promising for the clinical treatment of ischemic diseases.
- 23 September 2013
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 10 (10) , 3676-3683
Open AccessSynergistically Combined Gene Delivery for Enhanced VEGF Secretion and Antiapoptosis
With current pharmacological treatments, preventing the remodeling of the left ventricle and the progression to heart failure is a difficult task. Gene therapy is considered to provide a direct treatment to the long-term complications of ischemic heart diseases. Although current gene therapies that use single molecular targets seem potentially possible, they have not achieved success in the treatment of ischemic diseases. With an efficient polymeric gene carrier, PAM-ABP, we designed a synergistically combined gene-delivery strategy to enhance vascular endothelial growth factor (VEGF) secretion and to prolong its antiapoptotic effects. A hypoxia-inducible plasmid expressing both hypoxia-inducible heme oxygenase-1 (HO-1) and the Src homology domain-2 containing tyrosine phosphatase-1 microRNA (miSHP-1) as well as a hypoxia-responsive VEGF plasmid were combined in this study. The positive feedback circuit between HO-1 and VEGF and the negative regulatory role of SHP-1 in angiogenesis enhance VEGF secretion synergistically. The synergy in VEGF secretion as a consequence of the gene combination and prolonged HO-1 activity was confirmed in hypoxic cardiomyocytes and cardiomyocyte apoptosis under hypoxia and was decreased synergistically. These results suggest that the synergistic combination of VEGF, HO-1, and miSHP-1 may be promising for the clinical treatment of ischemic diseases.